Bevacizumab Concept

subject area of

• A Distinct Advantage to Intraarterial Delivery of ⁸⁹Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood–Brain Barrier  Academic Article
• A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial  Academic Article
• A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer  Academic Article
• A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial  Academic Article
• Adjuvant Chemotherapy With or Without Biologics Including Antiangiogenics and Monoclonal Antibodies Targeting EGFR and EpCAM in Colorectal Cancer: A Systematic Review and Meta-analysis  Academic Article
• Adverse Gastrointestinal Events with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Nested Case–Control Study  Academic Article
• Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study  Academic Article
• Aqueous Humor Cytokines and Long-Term Response to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema  Academic Article
• Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.  Academic Article
• Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial  Academic Article
• Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration  Academic Article
• Changes in plasma hormones and heart rate variability in patients receiving the cardiotoxic anti-cancer agent bevacizumab  Academic Article
• Displacement Affinity Release of Antibodies from Injectable Hydrogels  Academic Article
• Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer  Academic Article
• Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme  Academic Article
• Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial  Academic Article
• First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study  Academic Article
• First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients  Academic Article
• Increased incidence of retinopathy of prematurity and evolving treatment modalities at a Canadian tertiary centre  Academic Article
• MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial  Academic Article
• Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials  Conference Paper
• Metastatic renal cell cancer treatments: An indirect comparison meta-analysis  Academic Article
• Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer  Academic Article
• Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial  Academic Article
• Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial  Academic Article
• Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma  Academic Article
• Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials  Academic Article
• Safety of bevacizumab in metastatic breast cancer patients undergoing surgery  Academic Article
• Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center  Academic Article
• Seasonal and Environmental Variations in Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor Injection: A Six-year Review  Academic Article
• Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF165  Academic Article
• Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial  Academic Article
• Stroke Rates after Introduction of Vascular Endothelial Growth Factor Inhibitors for Macular Degeneration: A Time Series Analysis  Academic Article
• Targeted therapy for metastatic renal cell carcinoma  Academic Article
• The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure  Academic Article
• The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review  Academic Article
• Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline  Academic Article
• Treat‐and‐extend regimens of anti‐vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta‐analysis  Academic Article
• Using bevacizumab to treat metastatic cancer: UK consensus guidelines  Academic Article